Drug profile · INN
tremelimumab
IMJUDO
tremelimumab (IMJUDO) is a cytotoxic t-lymphocyte protein 4 inhibitor. Associated with AstraZeneca.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01FX20
Patents linked 0
Pipeline programs 24
News articles 1
Drug details — tremelimumab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 24
- Data quality
- 0.83
Quick answer
tremelimumab (IMJUDO) is a cytotoxic t-lymphocyte protein 4 inhibitor. Associated with AstraZeneca.
Key facts
INN tremelimumab
Brand IMJUDO
Mechanism Cytotoxic T-lymphocyte protein 4 inhibitor
Target Cytotoxic T-lymphocyte protein 4
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX20
Originator AstraZeneca
Mechanism of action
Cytotoxic T-lymphocyte protein 4 inhibitor
Primary target: Cytotoxic T-lymphocyte protein 4
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tremelimumab?
tremelimumab (IMJUDO) is a cytotoxic t-lymphocyte protein 4 inhibitor. Associated with AstraZeneca.
What is the brand name for tremelimumab?
IMJUDO is a marketed brand name for tremelimumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.